Stock CRDL CARDIOL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Market Closed - Toronto S.E.
Other stock markets
 04:50:53 2024-07-05 pm EDT 		5-day change 1st Jan Change
2.7 CAD 0.00% Intraday chart for Cardiol Therapeutics Inc. -1.10% +145.45%
Jun. 26 ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target MT
Jun. 13 Sector Update: Health Care Stocks Ease Late Afternoon MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
NE
ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target
MT
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
NE
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
AQ
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT
Cardiol Therapeutics Shares Fall After Report or Phase II Data for CardiolRx in Recurrent Pericarditis
MT
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
NE
Cardiol Therapeutics Inc. Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis
CI
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
AQ
Sector Spotlight: Orphan Drug Developers With Significant Upside
AQ
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
AQ
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
AQ
Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $8 From $6, Maintains Buy Rating
MT
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 (EXPRESSED IN CANADIAN DOLLARS) - Form 6-K
PU
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure
MT
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
NE
Cardiol Therapeutics Inc. Presents Phase II Archer Trial at the World Congress on Acute Heart Failure 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRDL Stock
  4. News Cardiol Therapeutics Inc.